HCW Biologics Inc. (HCWB)

NASDAQ: HCWB · IEX Real-Time Price · USD
1.760
0.00 (0.00%)
Mar 28, 2024, 3:59 PM EDT - Market closed

Total Valuation

HCW Biologics has a market cap or net worth of $64.19 million. The enterprise value is $59.30 million.

Market Cap 64.19M
Enterprise Value 59.30M

Important Dates

The next estimated earnings date is Tuesday, May 7, 2024, before market open.

Earnings Date May 7, 2024
Ex-Dividend Date n/a

Share Statistics

HCW Biologics has 35.97 million shares outstanding. The number of shares has increased by 0.26% in one year.

Shares Outstanding 35.97M
Shares Change (YoY) +0.26%
Shares Change (QoQ) +0.05%
Owned by Insiders (%) 54.72%
Owned by Institutions (%) 2.97%
Float 16.94M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 111.44
Forward PS 69.93
PB Ratio 2.69
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 102.96
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.27.

Current Ratio 2.56
Quick Ratio 2.20
Debt / Equity 0.27
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -47.00

Financial Efficiency

Return on equity (ROE) is -64.40% and return on invested capital (ROIC) is -68.27%.

Return on Equity (ROE) -64.40%
Return on Assets (ROA) -47.70%
Return on Capital (ROIC) -68.27%
Revenue Per Employee $13,091
Profits Per Employee -$448,466
Employee Count 44
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +32.33% in the last 52 weeks. The beta is 0.92, so HCW Biologics's price volatility has been similar to the market average.

Beta (1Y) 0.92
52-Week Price Change +32.33%
50-Day Moving Average 1.37
200-Day Moving Average 1.64
Relative Strength Index (RSI) 63.53
Average Volume (30 Days) 16,900

Short Selling Information

The latest short interest is 22,012, so 0.06% of the outstanding shares have been sold short.

Short Interest 22,012
Short Previous Month 23,960
Short % of Shares Out 0.06%
Short % of Float 0.13%
Short Ratio (days to cover) 2.62

Income Statement

In the last 12 months, HCW Biologics had revenue of $576,019 and -$19.73 million in losses. Loss per share was -$0.56.

Revenue 576,019
Gross Profit 576,019
Operating Income -20.62M
Pretax Income -19.73M
Net Income -19.73M
EBITDA -18.20M
EBIT -19.32M
Loss Per Share -$0.56
Full Income Statement

Balance Sheet

The company has $11.22 million in cash and $6.33 million in debt, giving a net cash position of $4.89 million or $0.14 per share.

Cash & Cash Equivalents 11.22M
Total Debt 6.33M
Net Cash 4.89M
Net Cash Per Share $0.14
Equity / Book Value 23.87M
Book Value Per Share 0.66
Working Capital 8.43M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$22.41 million and capital expenditures -$2.56 million, giving a free cash flow of -$24.96 million.

Operating Cash Flow -22.41M
Capital Expenditures -2.56M
Free Cash Flow -24.96M
FCF Per Share -$0.70
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -3,579.08% and -3,425.67%.

Gross Margin 100.00%
Operating Margin -3,579.08%
Pretax Margin -3,425.67%
Profit Margin -3,425.67%
EBITDA Margin -3,159.62%
EBIT Margin -3,354.29%
FCF Margin -4,333.94%

Dividends & Yields

HCW Biologics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -0.26%
Shareholder Yield -0.26%
Earnings Yield -30.74%
FCF Yield -38.89%

Analyst Forecast

The average price target for HCW Biologics is $9.00, which is 411.36% higher than the current price. The consensus rating is "Strong Buy".

Price Target $9.00
Price Target Difference 411.36%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (5Y) 99.63%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

HCW Biologics has an Altman Z-Score of -0.56 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.56
Piotroski F-Score 1